The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer - In Reply

Research output: Contribution to journalLetter

Original languageEnglish
JournalJAMA oncology
DOIs
Publication statusPublished - Jan 1 2019

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this